Literature DB >> 34790364

Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators.

Riccardo Lemini1, Tamara Díaz Vico1, Denslow A Trumbull2, Kristopher Attwood3, Aaron C Spaulding4, Enrique F Elli1, Dorin T Colibaseanu1, Moshim Kukar5, Emmanuel Gabriel1.   

Abstract

BACKGROUND: Determining the best approach for esophageal cancer and predicting accurate prognosis are critical. Multiple studies evaluated characteristics associated with overall survival, and several prediction models have been developed. This study aimed to evaluate existing models and perform external validation of selected models.
METHODS: A retrospective investigation of a multi-site institutional enterprise for patients with a diagnosis of esophageal cancer between 2013-2014 was performed. Selected survival prediction models included the Roswell Park Comprehensive Cancer Center (RPCCC) calculator, Oregon Health & Science University (OHSU) calculator, and two nomograms published by Shapiro et al. and Sun et al. One-year overall survival, level of agreement, and performance for each model were evaluated.
RESULTS: A total of 104 patients were included and used to assess the prediction models. One-year overall survival was 0.76. Different calculators tended to rank patients similarly; however, they did not agree on predicted overall survival. The least disparity in correlation was observed between OHSU and Shapiro calculators. Shapiro's model achieved the highest performance [area under the curve (AUC) =0.63].
CONCLUSIONS: Selected models showed fair results in estimating individual overall survival, although none achieved a high performance. While these tools may support the decision-making process for esophageal cancer patients, their implementation in clinical practice requires improved refinement to optimize their clinical utility. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; calculator; neoadjuvant chemoradiation; nomogram; overall survival (OS)

Year:  2021        PMID: 34790364      PMCID: PMC8576235          DOI: 10.21037/jgo-20-337

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  37 in total

Review 1.  Barrett's esophagus: cancer and molecular biology.

Authors:  Michael K Gibson; Arashinder S Dhaliwal; Nicholas J Clemons; Wayne A Phillips; Katerina Dvorak; Daniel Tong; Simon Law; E Daniel Pirchi; Jari Räsänen; Mark J Krasna; Kaushal Parikh; Kausilia K Krishnadath; Yu Chen; Leonard Griffiths; Benjamin J Colleypriest; J Mark Farrant; David Tosh; Kiron M Das; Manisha Bajpai
Journal:  Ann N Y Acad Sci       Date:  2013-10       Impact factor: 5.691

2.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma.

Authors:  F Turati; I Tramacere; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

4.  A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study.

Authors:  Xin Tang; Xiaojuan Zhou; Yanying Li; Xue Tian; Yongsheng Wang; Meijuan Huang; Li Ren; Lin Zhou; Zhenyu Ding; Jiang Zhu; Yong Xu; Feng Peng; Jin Wang; You Lu; Youling Gong
Journal:  Ann Surg Oncol       Date:  2018-10-24       Impact factor: 5.344

5.  Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis.

Authors:  Robert Eil; Brian S Diggs; Samuel J Wang; James P Dolan; John G Hunter; Charles R Thomas
Journal:  Cancer       Date:  2013-11-05       Impact factor: 6.860

6.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 7.  Prognostic factors in esophageal cancer treated with curative intent.

Authors:  Véronique Vendrely; Vincent Launay; Haythem Najah; Denis Smith; Denis Collet; Caroline Gronnier
Journal:  Dig Liver Dis       Date:  2018-08-09       Impact factor: 4.088

8.  Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Andrew R Davies; James A Gossage; Janine Zylstra; Fredrik Mattsson; Jesper Lagergren; Nick Maisey; Elizabeth C Smyth; David Cunningham; William H Allum; Robert C Mason
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

9.  Increased population prevalence of reflux and obesity in the United Kingdom compared with Sweden: a potential explanation for the difference in incidence of esophageal adenocarcinoma.

Authors:  Hedvig E Löfdahl; Athene Lane; Yunxia Lu; Pernilla Lagergren; Richard F Harvey; Jane M Blazeby; Jesper Lagergren
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-02       Impact factor: 2.566

10.  Stage II-III colon cancer: a comparison of survival calculators.

Authors:  Riccardo Lemini; Kristopher Attwood; Stacey Pecenka; Juliet Grego; Aaron C Spaulding; Steven Nurkin; Dorin T Colibaseanu; Emmanuel Gabriel
Journal:  J Gastrointest Oncol       Date:  2018-12
View more
  3 in total

1.  Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery.

Authors:  Zhenjiang Guo; Honghai Guo; Yuan Tian; Ze Zhang; Qun Zhao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy.

Authors:  Yongkui Yu; Wei Wang; Zimin Qin; Haomiao Li; Qi Liu; Haibo Ma; Haibo Sun; Thomas L Bauer; Jose M Pimiento; Emmanuel Gabriel; Thomas Birdas; Yin Li; Wenqun Xing
Journal:  Ann Transl Med       Date:  2022-01

3.  A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection.

Authors:  Changsen Leng; Yingying Cui; Junying Chen; Kexi Wang; Hong Yang; Jing Wen; Jianhua Fu; Qianwen Liu
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.